Azithromycin Fails Preschool Wheezing Trial Despite Killing Bacteria

A five-day course of azithromycin cleared the bacteria it was supposed to clear in 58.7% of preschoolers wheezing in the emergency department, against 11.4% on placebo. The kids on the antibiotic still wheezed, coughed and slept just as badly as the kids on the dummy syrup.

Investigators stopped the 840-child trial early for futility, and the result, published May 18 in the New England Journal of Medicine, lands as the most definitive evidence yet that the antibiotic has no role in routine care of moderate-to-severe preschool wheeze, even when a nasal swab comes back positive for the usual respiratory bacteria.

What the AZ-SWED Trial Measured

The AZ-SWED study, short for Azithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department, ran across eight pediatric emergency departments in the United States under the Pediatric Emergency Care Applied Research Network registry record. It enrolled children aged 18 to 59 months who presented with moderate or severe acute wheeze, then randomized them to azithromycin at 12 mg per kilogram once daily for five days, or matching placebo.

The primary endpoint was the sum of daily scores on the Asthma Flare-up Diary for Young Children (ADYC, a parent-completed instrument capturing breathing, cough, appetite and mood), totaled over five days. The score range runs from 5 to 35, with higher numbers meaning worse symptoms.

A pre-planned analysis split the cohort by nasopharyngeal swab result, because earlier observational work had flagged Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae as more common in children with recurrent wheeze. The data and safety monitoring board pulled the trial at roughly 60% enrollment after both bacterial subgroups missed the conditional-power threshold, with conditional power calculated at 16% or less.

• 840 children randomized across 8 pediatric emergency departments
• Ages 18 to 59 months with moderate or severe acute wheezing
• Azithromycin 12 mg/kg once daily for 5 days versus matching placebo
• 521 of 840 tested positive for pathogenic bacteria; roughly 86% carried a respiratory virus, with rhinovirus the most common
• Stopped early for futility after a planned interim analysis

Bacterial Clearance Without Symptom Relief

Among the 521 children whose swabs grew one of the three pathogens, the median five-day ADYC score was 9.59 in the antibiotic arm and 9.72 on placebo. In the 319 who tested negative, the medians sat at 9.30 versus 9.10. A statistician would call those gaps noise.

Bacterial clearance told a very different story. On follow-up sampling, 58.7% of antibiotic-treated children had cleared their initial pathogen, against 11.4% in the placebo arm. The drug did exactly what a macrolide (a class of antibiotic that includes erythromycin and clarithromycin) is supposed to do. The children’s lungs did not care.

Secondary endpoints reinforced the null result. Emergency department length of stay, hospital length of stay, and return visits or hospitalizations within 72 hours were statistically indistinguishable between the two arms. Adverse-event rates tracked together, and so did rates of new macrolide resistance.

Why Doctors Reach for Azithromycin in Wheeze

The prescribing instinct is not random. Observational studies have repeatedly linked recurrent preschool wheeze with nasal carriage of S. pneumoniae, M. catarrhalis and H. influenzae, and azithromycin combines respectable activity against those organisms with anti-inflammatory effects on airway tissue. That biological story made the drug attractive in a clinical scenario that frustrates parents and clinicians alike: a three-year-old struggling to breathe at 2 a.m., the second time this month.

A 2015 randomized trial known as APRIL, led by Leonard Bacharier and supported by the National Heart, Lung, and Blood Institute through its AsthmaNet program, tipped the scale further. Among preschoolers with histories of recurrent severe lower respiratory illness, early azithromycin started at the first cold symptom reduced the risk of progression to severe symptoms by 36%. The NHLBI BioLINCC archive of the APRIL dataset still lists that trial as one of the field’s pivotal references on macrolide use in young wheezers.

AZ-SWED is built to answer a different question. APRIL tested prevention of escalation when the drug is given at the first cold symptom in children with prior recurrent wheeze. AZ-SWED tested treatment after the child has already arrived in the emergency department with a moderate or severe episode. The two trials sit at different points on the disease timeline, and they now point in different directions.

What Changes for Pediatric Emergency Care

Pediatric emergency departments handle roughly 2.2 million wheezing visits in the 2-to-5-year-old age band every year in the United States, and about 30,000 children under five are admitted to hospital for wheezing annually. The share who walk out holding an azithromycin prescription has never been counted nationally with precision, but stewardship audits at large children’s hospitals routinely flag wheeze and bronchiolitis as drivers of inappropriate macrolide use.

We can say with a high degree of certainty that children who come to the doctor’s office or the emergency room with a severe wheezing episode should not be given azithromycin or any antibiotic.

That is Fernando Martinez, director of the Asthma and Airway Disease Research Center at the University of Arizona College of Medicine in Tucson and the trial’s senior investigator, in a University of Arizona statement accompanying the publication. Lead author Kurt Denninghoff, professor of emergency medicine at the same college, was first author on the New England Journal paper, with the data coordinating center based at the University of Utah.

Antibiotic Stewardship in Children Under Five

Azithromycin sits among the most prescribed antibiotics in U.S. pediatric outpatient and emergency settings. Resistance among S. pneumoniae has been climbing for two decades, and the Centers for Disease Control antibiotic-use stewardship guidance has flagged macrolide overuse for upper-respiratory and viral illnesses as a priority concern. The AZ-SWED finding folds neatly into that picture: roughly 86% of enrolled children carried a respiratory virus, meaning a viral process was driving most of these visits in the first place.

The trial’s null result removes one of the last remaining randomized arguments for reaching for the drug at hour zero of an acute wheezing visit. It does not contradict the early-start APRIL strategy, which targets a different patient and a different moment.

Standard acute care for moderate or severe preschool wheeze continues to center on inhaled bronchodilators such as albuterol and, when clinically indicated, a short course of oral corticosteroids. Adding a macrolide to that regimen on the assumption it will help is the practice the new data argue against. The drug did its microbiological job and nothing else, and that is what the field has been waiting to know with this much certainty.

Frequently Asked Questions

Does Azithromycin Help When a Preschooler Is Wheezing in the Emergency Room?

No. The AZ-SWED trial of 840 children aged 18 to 59 months found no improvement in wheezing-related symptoms over five days, whether or not the child’s nasopharynx tested positive for pathogenic bacteria. Median symptom scores were essentially identical between the antibiotic and placebo groups, and so were return visits within 72 hours.

Why Was Azithromycin Ever Used for Preschool Wheeze in the First Place?

Observational studies linked recurrent wheezing with nasal carriage of bacteria such as Streptococcus pneumoniae, and a 2015 trial named APRIL showed a 36% reduction in severe lower respiratory illness when azithromycin was started at the first cold symptom in children with prior recurrent episodes. The new trial studied a different scenario, treatment after moderate or severe wheeze has already developed, and produced a different answer.

Did the Drug at Least Clear the Bacteria?

Yes. Bacterial clearance reached 58.7% in the antibiotic arm versus 11.4% in placebo, a roughly five-fold difference. The catch is that clearance did not translate into faster recovery, shorter emergency stay, or fewer return visits. The microbiological win was a clinical wash.

What About Side Effects and Antibiotic Resistance?

Adverse-event rates and rates of newly detected macrolide resistance looked similar between the two arms in this specific trial. That said, broader public-health concern around community macrolide resistance is real, and unnecessary antibiotic courses contribute to it over time.

What Should Parents Do if Their Preschooler Is Wheezing Severely?

Seek prompt medical attention. Standard acute care for moderate or severe preschool wheeze centers on inhaled bronchodilators such as albuterol and, where indicated by a clinician, oral corticosteroids. The new trial argues against routinely adding an antibiotic to that regimen at the emergency department visit.

Does This Affect the Early-Azithromycin APRIL Strategy?

No. APRIL studied an early start at the first cold symptom in children with a history of recurrent severe wheeze, not children already in the emergency department with an active moderate or severe episode. The two findings address different clinical decisions and remain compatible.

Where Was the Trial Published and Who Funded It?

Results appeared May 18 in the New England Journal of Medicine and were presented the same week at the American Thoracic Society International Conference in Orlando. Funding came from the National Heart, Lung, and Blood Institute under grants UG3/UH3HL147016 and U24HL147018, channelled through the Pediatric Emergency Care Applied Research Network.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Decisions about diagnosis or treatment of a wheezing child should be made by a qualified clinician who knows the patient. Trial findings reported here are accurate as of publication on May 19, 2026; clinical guidelines may evolve as additional analyses appear.